These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 34363606)

  • 41. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhang M; Zhou HR
    Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis.
    Li N; Zhou G; Zheng Y; Lv D; Zhu X; Wei P; Zheng M; Liu S; Zhou E; Sun W; Zhang L
    PLoS One; 2022; 17(1):e0261986. PubMed ID: 35020750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
    Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
    Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.
    Gronda EG; Vanoli E; Iacoviello M; Urbinati S; Caldarola P; Colivicchi F; Gabrielli D
    Heart Fail Rev; 2023 May; 28(3):723-732. PubMed ID: 35098383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
    Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
    Zanoli L; Granata A; Lentini P; Rastelli S; Fatuzzo P; Rapisarda F; Castellino P
    ScientificWorldJournal; 2015; 2015():317507. PubMed ID: 25785281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
    van der Aart-van der Beek AB; de Boer RA; Heerspink HJL
    Nat Rev Nephrol; 2022 May; 18(5):294-306. PubMed ID: 35145275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice.
    Evans M; Morgan AR; Whyte MB; Hanif W; Bain SC; Kalra PA; Davies S; Dashora U; Yousef Z; Patel DC; Strain WD
    Drugs; 2022 Feb; 82(2):97-108. PubMed ID: 34932209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
    Pecoits-Filho R; Perkovic V
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
    [No Abstract]   [Full Text] [Related]  

  • 53. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review.
    Khiali S; Taban-Sadeghi M; Sarbakhsh P; Khezerlouy-Aghdam N; Rezagholizadeh A; Asham H; Entezari-Maleki T
    J Clin Pharmacol; 2023 Dec; 63(12):1307-1323. PubMed ID: 37455561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
    Benvenuto M; Panzarella G; Shehaj E; Valenti C; Caldarola P; Colivicchi F; Gabrielli D; Iacoviello M;
    G Ital Cardiol (Rome); 2023 Mar; 24(3):188-195. PubMed ID: 36853155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
    Singhal R; Hechanova LA
    Curr Cardiol Rep; 2022 Mar; 24(3):183-189. PubMed ID: 35147891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.